Role of Interferon-λ in allergic asthma

Journal of Innate Immunity

Volumn 7, Issue 3, 2015, Pages 224-230

  Koch, Sonja ^a   Finotto, Susetta ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Adaptive immunity; Allergic asthma; Interferon

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 13; INTERLEUKIN 28; INTERLEUKIN 29; INTERLEUKIN 5; MESSENGER RNA; TRANSCRIPTION FACTOR FOXP3; IL29 PROTEIN, HUMAN; IL5 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ADAPTIVE IMMUNITY; ALLERGIC ASTHMA; ANTIPROLIFERATIVE ACTIVITY; ANTIVIRAL ACTIVITY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE EXACERBATION; DISEASE SEVERITY; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IN VITRO STUDY; LYMPHOCYTE MIGRATION; LYMPHOCYTE PROLIFERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; RESPIRATORY TRACT ALLERGY; REVIEW; SIGNAL TRANSDUCTION; TH2 CELL; UPREGULATION; VIRUS INFECTION; VIRUS INHIBITION; VIRUS REPLICATION; ANIMAL; ASTHMA; IMMUNOLOGY; PATHOLOGY;

ADAPTIVE IMMUNITY; ANIMALS; ASTHMA; HUMANS; INTERLEUKIN-13; INTERLEUKIN-5; INTERLEUKINS; RNA, MESSENGER; TH2 CELLS;

EID: 84929026704     PISSN: 1662811X     EISSN: 16628128     Source Type: Journal    
DOI: 10.1159/000369459     Document Type: Review

References (50)

1. Boyce JA, Broide D, Matsumoto K, Bochner BS: Advances in mechanisms of asthma, allergy, and immunology in 2008. J Allergy Clin Immunol 2009; 123: 569-574.
2. Hamid Q, Tulic M: Immunobiology of asthma. Annu Rev Physiol 2009; 71: 489-507.
3. Umetsu DT, DeKruyff RH: The regulation of allergy and asthma. Immunol Rev 2006; 212: 238-255.
4. Holgate ST: Innate and adaptive immune responses in asthma. Nat Med 2012; 18: 673-683.
5. Kim HY, DeKruyff RH, Umetsu DT: The many paths to asthma: phenotype shaped by innate and adaptive immunity. Nat Immunol 2010; 11: 577-584.
6. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, Langer JA, Sheikh F, Dickensheets H, Donnelly RP: IFN-lambdas mediate antiviral protection through a distinct class ii cytokine receptor complex. Nat Immunol 2003; 4: 69-77.
7. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J, Ostrander C, Dong D, Shin J, Presnell S, Fox B, Haldeman B, Cooper E, Taft D, Gilbert T, Grant FJ, Tackett M, Krivan W, McKnight G, Clegg C, Foster D, Klucher KM: IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003; 4: 63-68.
8. Kotenko SV: IFN-lambdas. Curr Opin Immunol 2011; 23: 583-590.
9. Lasfar A, Lewis-Antes A, Smirnov SV, Anantha S, Abushahba W, Tian B, Reuhl K, Dickensheets H, Sheikh F, Donnelly RP, Raveche E, Kotenko SV: Characterization of the mouse IFN-lambda ligand-receptor system: IFNlambdas exhibit antitumor activity against B16 melanoma. Cancer Res 2006; 66: 4468-4477.
10. Lauterbach H, Bathke B, Gilles S, Traidl-Hoffmann C, Luber CA, Fejer G, Freudenberg MA, Davey GM, Vremec D, Kallies A, Wu L, Shortman K, Chaplin P, Suter M, O'Keeffe M, Hochrein H: Mouse CD8alpha+ DCs and human BDCA3+ DCs are major producers of IFN-lambda in response to poly IC. J Exp Med 2010; 207: 2703-2717.
11. Li M, Liu X, Zhou Y, Su SB: Interferon-lambdas: the modulators of antivirus, antitumor, and immune responses. J Leukoc Biol 2009; 86: 23-32.
12. Srinivas S, Dai J, Eskdale J, Gallagher GE, Megjugorac NJ, Gallagher G: Interferon-lambda1 (interleukin-29) preferentially down-regulates interleukin-13 over other T helper type 2. cytokine responses in vitro. Immunology 2008; 125: 492-502.
13. Koltsida O, Hausding M, Stavropoulos A, Koch S, Tzelepis G, Ubel C, Kotenko SV, Sideras P, Lehr HA, Tepe M, Klucher KM, Doyle SE, Neurath MF, Finotto S, Andreakos E: IL-28a (IFN-2) modulates lung DC function to promote Th1 immune skewing and suppress allergic airway disease. EMBO Mol Med 2011; 3: 348-361.
14. Coccia EM, Severa M, Giacomini E, Monneron D, Remoli ME, Julkunen I, Cella M, Lande R, Uze G: Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur J Immunol 2004; 34: 796-805.
15. Khaitov MR, Laza-Stanca V, Edwards MR, Walton RP, Rohde G, Contoli M, Papi A, Stanciu LA, Kotenko SV, Johnston SL: Respiratory virus induction of alpha-, beta-and lambda-interferons in bronchial epithelial cells and peripheral blood mononuclear cells. Allergy 2009; 64: 375-386.
16. Wolk K, Witte K, Witte E, Proesch S, Schulze-Tanzil G, Nasilowska K, Thilo J, Asadullah K, Sterry W, Volk HD, Sabat R: Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes. J Leukoc Biol 2008; 83: 1181-1193.
17. Siren J, Pirhonen J, Julkunen I, Matikainen S: IFN-alpha regulates TLR-dependent gene expression of IFN-alpha, IFN-beta, IL-28, and IL-29. J Immunol 2005; 174: 1932-1937.
18. Durbin RK, Kotenko SV, Durbin JE: Interferon induction and function at the mucosal surface. Immunol Rev 2013; 255: 25-39.
19. Sommereyns C, Paul S, Staeheli P, Michiels T: IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 2008; 4:e1000017.
20. Kelly C, Klenerman P, Barnes E: Interferon lambdas: the next cytokine storm. Gut 2011; 60: 1284-1293.
21. Doyle SE, Schreckhise H, Khuu-Duong K, Henderson K, Rosler R, Storey H, Yao L, Liu H, Barahmand-pour F, Sivakumar P, Chan C, Birks C, Foster D, Clegg CH, Wietzke-Braun P, Mihm S, Klucher KM: Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 2006; 44: 896-906.
22. Mennechet FJ, Uze G: Interferon-lambdatreated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. Blood 2006; 107: 4417-4423.
23. Langer JA, Cutrone EC, Kotenko S: The class II cytokine receptor (CRF2) family: overview and patterns of receptor-ligand interactions. Cytokine Growth Factor Rev 2004; 15: 33-48.
24. Dumoutier L, Tounsi A, Michiels T, Sommereyns C, Kotenko SV, Renauld JC: Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. J Biol Chem 2004; 279: 32269-32274.
25. Renauld JC: Class II cytokine receptors and their ligands: key antiviral and inflammatory modulators. Nat Rev Immunol 2003; 3: 667-676.
26. Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, Otte JM, Diebold J, Diepolder H, Adler B, Auernhammer CJ, Goke B, Dambacher J: IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am J Physiol Gastrointest Liver Physiol 2005; 289: G960-G968.
27. Zhou Z, Hamming OJ, Ank N, Paludan SR, Nielsen AL, Hartmann R: Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J Virol 2007; 81: 7749-7758.
28. Wakashin H, Hirose K, Maezawa Y, Kagami S, Suto A, Watanabe N, Saito Y, Hatano M, Tokuhisa T, Iwakura Y, Puccetti P, Iwamoto I, Nakajima H: IL-23 and Th17 cells enhance Th2-cell-mediated eosinophilic airway inflammation in mice. Am J Respir Crit Care Med 2008; 178: 1023-1032.
29. Wilson RH, Whitehead GS, Nakano H, Free ME, Kolls JK, Cook DN: Allergic sensitization through the airway primes Th17-dependent neutrophilia and airway hyperresponsiveness. Am J Respir Crit Care Med 2009; 180: 720-730.
30. Joetham A, Takeda K, Taube C, Miyahara N, Matsubara S, Koya T, Rha YH, Dakhama A, Gelfand EW: Naturally occurring lung CD4(+)CD25(+) T cell regulation of airway allergic responses depends on IL-10 induction of TGF-beta. J Immunol 2007; 178: 1433-1442.
31. Kearley J, Barker JE, Robinson DS, Lloyd CM: Resolution of airway inflammation and hyperreactivity after in vivo transfer of CD4+CD25+ regulatory T cells is interleukin
32. dependent. J Exp Med 2005; 202: 1539-1547.
33. Jordan WJ, Eskdale J, Srinivas S, Pekarek V, Kelner D, Rodia M, Gallagher G: Human interferon lambda-1 (IFN-lambda1/IL-29) modulates the Th1/Th2 response. Genes Immun 2007; 8: 254-261.
34. Li Y, Gao Q, Yuan X, Zhou M, Peng X, Liu X, Zheng X, Xu D, Li M: Adenovirus expressing IFN-lambda1 (IL-29) attenuates allergic airway inflammation and airway hyperreactivity in experimental asthma. Int Immunopharmacol 2014; 21: 156-162.
35. Doganci A, Eigenbrod T, Krug N, De Sanctis GT, Hausding M, Erpenbeck VJ, Haddad el-B, Lehr HA, Schmitt E, Bopp T, Kallen KJ, Herz U, Schmitt S, Luft C, Hecht O, Hohlfeld JM, Ito H, Nishimoto N, Yoshizaki K, Kishimoto T, Rose-John S, Renz H, Neurath MF, Galle PR, Finotto S: The IL-6R alpha chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo. J Clin Invest 2005; 115: 313-325.
36. Finotto S, Eigenbrod T, Karwot R, Boross I, Doganci A, Ito H, Nishimoto N, Yoshizaki K, Kishimoto T, Rose-John S, Galle PR, Neurath MF: Local blockade of IL-6R signaling induces lung CD4+ T cell apoptosis in a murine model of asthma via regulatory T cells. Int Immunol 2007; 19: 685-693.
37. Karwot R, Ubel C, Bopp T, Schmitt E, Finotto S: Increased immunosuppressive function of CD4(+)CD25(+)Foxp3(+)GITR+ T regulatory cells from NFATc2((-/-)) mice controls allergen-induced experimental asthma. Immunobiology 2012; 217: 905-911.
38. Bullens DM, Decraene A, Dilissen E, Meyts I, De Boeck K, Dupont LJ, Ceuppens JL: Type III IFN-lambda mRNA expression in sputum of adult and school-aged asthmatics. Clin Exp Allergy 2008; 38: 1459-1467.
39. Contoli M, Message SD, Laza-Stanca V, Edwards MR, Wark PA, Bartlett NW, Kebadze T, Mallia P, Stanciu LA, Parker HL, Slater L, Lewis-Antes A, Kon OM, Holgate ST, Davies DE, Kotenko SV, Papi A, Johnston SL: Role of deficient type III interferon-lambda production in asthma exacerbations. Nat Med 2006; 12: 1023-1026.
40. Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ: Asthma and wheezing in the first six years of life. The Group Health Medical Associates. N Engl J Med 1995; 332: 133-138.
41. Miller EK, Lu X, Erdman DD, Poehling KA, Zhu Y, Griffin MR, Hartert TV, Anderson LJ, Weinberg GA, Hall CB, Iwane MK, Edwards KM; New Vaccine Surveillance Network: Rhinovirus-associated hospitalizations in young children. J Infect Dis 2007; 195: 773-781.
42. Miller EK, Hernandez JZ, Wimmenauer V, Shepherd BE, Hijano D, Libster R, Serra ME, Bhat N, Batalle JP, Mohamed Y, Reynaldi A, Rodriguez A, Otello M, Pisapia N, Bugna J, Bellabarba M, Kraft D, Coviello S, Ferolla FM, Chen A, London SJ, Siberry GK, Williams JV, Polack FP: A mechanistic role for type III IFN-lambda1 in asthma exacerbations mediated by human rhinoviruses. Am J Respir Crit Care Med 2012; 185: 508-516.
43. Akdis CA: Therapies for allergic inflammation: refining strategies to induce tolerance. Nat Med 2012; 18: 736-749.
44. Corren J, Busse W, Meltzer EO, Mansfield L, Bensch G, Fahrenholz J, Wenzel SE, Chon Y, Dunn M, Weng HH, Lin SL: A randomized, controlled, phase 2 study of amg 317, an IL-4ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med 2010; 181: 788-796.
45. Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M: Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007; 370: 1422-1431.
46. Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, Harris JM, Scheerens H, Wu LC, Su Z, Mosesova S, Eisner MD, Bohen SP, Matthews JG: Lebrikizumab treatment in adults with asthma. N Engl J Med 2011; 365: 1088-1098.
47. Finotto S, Hausding M, Doganci A, Maxeiner JH, Lehr HA, Luft C, Galle PR, Glimcher LH: Asthmatic changes in mice lacking T-bet are mediated by IL-13. Int Immunol 2005; 17: 993-1007.
48. Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS: Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003; 167: 199-204.
49. Kips JC, O'Connor BJ, Langley SJ, Woodcock A, Kerstjens HA, Postma DS, Danzig M, Cuss F, Pauwels RA: Effect of sch55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: A pilot study. Am J Respir Crit Care Med 2003; 167: 1655-1659.
50. Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, Hargreave FE, O'Byrne PM: Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. New Engl J Med 2009; 360: 985-993.